MEA Tuberculin Market

MEA Tuberculin Market Size (2024 to 2029)

The Middle East and Africa Tuberculin market size is projected to grow from USD 26.54 million in 2024 to 33.17 million in 2029, at a CAGR of 4.56%.

People have been able to use these treatments to accelerate their growth rate as economies have changed and disposable income has increased due to greater government initiatives to secure the supply of these pharmaceuticals and raise public knowledge. In addition, technological advancements have been used to improve the efficacy of these medications and expand their market in this region.

The tuberculin market in the Middle East and Africa is growing at a healthy rate, owing to an increase in the incidence of tuberculosis year over year. The need for tuberculosis drugs is increasing due to advancements in treatments. New medicine for the treatment of tuberculosis has been developed by the TB Alliance, a non-profit organization based in the United States. The TB Alliance received FDA approval in August 2019 for Pretomnid, a bedaquiline and linezolid combination regimen developed and intended to treat individuals with XDR-TB or intolerant non-responsive MDR-TB.

The Middle East and Africa tuberculin markets are likely to achieve new highs in the forecast period due to increased finances and investments from both the private and public sectors. Furthermore, various government-sponsored health-awareness programs worldwide promote the growth of the Middle East and Africa tuberculin business. Another key factor expected to enhance the tuberculin market's growth is increased research and development activities.

However, the increased number of medicine recalls is a significant barrier to market expansion. Manufacturers of tuberculosis medicines are noticing an upsurge in product recalls due to packaging or manufacturing flaws. Another stumbling obstacle to the Middle East and Africa market's progress is the high cost of drugs. Second-line therapy pharmaceuticals are more expensive than first-line therapy treatments and have more side effects and toxicity.

The adverse effects of tuberculin are limiting the market's growth. In a considerable number of cases, irritation, swelling, and discomfort at the injection site have been reported, putting the business on the decline.

This research report on the MEA Tuberculin Market has been segmented and sub-segmented into the following categories:

By Product Type:

• PPD-S
• PPD RT23

By Application:

• Human Use
• Animal Use

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The Middle East and Africa are expected to have a healthy growth rate in the foreseeable future. Some of the primary growing causes include rising tuberculosis incidence in Africa and favorable government policies that result in funding. Growing health consciousness and the growing economies of developing countries are also helping to improve the market. The test's results are known to be influenced by a variety of other factors, such as existing sickness and age, and hence must be interpreted with caution. Tuberculin market competitiveness is predicted to be boosted by technological developments in tuberculosis therapy.

The UAE is the region's largest market for the detection of latent TB. The UAE has one of the most advanced healthcare systems in the area. The UAE Vision 2022 National Agenda aims to construct a world-class healthcare system and position the country as a regional leader in the sector. According to Arab Health, the UAE's healthcare sector is undergoing structural changes, with rapid growth expected over the next five years, with AED103 billion ($28 billion) expected in 2022. A growing market in emerging economies and increased advances in tuberculosis diagnostics are driving the MEA Tuberculin market.

KEY MARKET PLAYERS:

The key manufacturers of the MEA Tuberculin market include Sanroad Biological, Japan BCG, Par Sterile, Sanofi Pasteur, Zoetis, SSI, Thermo Fisher, CNBG, CZ veterinaria.